超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Synthetic Biologics  
Synthetic Biologics, Inc(SYN.US)成立于2001年，原名「Adeona Pharmaceuticals」，總部位于美國密西根州安娜堡，為一家生物合成制藥公司，主要從事研究及開發肺動脈高壓(PAH)、多發性硬化癥、纖維肌痛，以及俗稱「漸凍人」的肌萎縮性脊髓側索硬化癥(ALS)之治療藥物。

Founded in 2001 with headquarters in Ann Arbor, Michigan, and offices in Rockville, Maryland, Synthetic Biologics, Inc. (NYSE Amex: SYN) is a biotechnology company focused on the development of product candidates to address serious diseases and unmet medical needs.

Synthetic Biologics is focused on the development of synthetic biologics, an emerging biological discipline that combines biology, engineering and informatics for the development of new therapeutic candidates. To this end, the Company has entered into two worldwide exclusive channel collaborations with Intrexon Corporation that allow for the utilization of Intrexon’s comprehensive suite of proprietary technologies and processes. Pursuant to the most recent collaboration, Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. The initial collaboration is focused on development and commercialization of a DNA-based therapeutic for the treatment of pulmonary arterial hypertension (PAH).
In addition, Synthetic Biologics is developing, or has partnered the development of, funded clinical programs to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia (partnered with Meda AB).